PURPOSE We evaluated changes in the numbers of microaneurysms (MAs) on fluorescein angiography (FA) and indocyanine green angiography (IA) in eyes with diabetic macular edema (DME) following intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents. METHODS Twenty-one eyes of 16 patients with DME were included in this retrospective study. All patients received an initial loading dose of three monthly injections of anti-VEGF agents; thereafter, they received a pro re nata regimen for at least 12 months of follow-up. FA and IA images were obtained before and at 6 months after the initial injection. RESULTS The median numbers of MAs significantly decreased from six (interquartile range [IQR] 3-7) MAs in early-phase FA, three (IQR 3-5) leaky MAs in late-phase FA, and two (IQR 1-4) MAs in late-phase IA at baseline to two (IQR 1-3) MAs in early-phase FA, one (IQR 0-2) leaky MA in late-phase FA, and one (IQR 0-2) MA in late-phase IA at 6 months (P < 0.0001 for all). Only the median numbers of MAs in late-phase IA at baseline and at 6 months were significantly higher in the recurrent DME group (13 eyes) than in the non-recurrent DME group (five eyes) (three [IQR 2-4] vs one [IQR 1-2], one [IQR 0.5-2] vs zero [P = 0.0185 and P = 0.009]). CONCLUSION Intravitreal injection of anti-VEGF agents reduced the numbers of MAs in patients with DME. The numbers of MAs detected by late-phase IA might be useful predictors of DME recurrence.

中文翻译：

---

抗血管内皮生长因子治疗后糖尿病性黄斑水肿微动脉瘤数量减少：对吲哚菁绿血管造影术指导的难治性微动脉瘤的意义。

目的我们评估了玻璃体内注射抗血管内皮生长因子（VEGF）药物后，糖尿病性黄斑水肿（DME）眼中荧光素血管造影（FA）和吲哚菁绿色血管造影（IA）的微动脉瘤（MAs）数量的变化。方法这项回顾性研究包括16例DME患者的21眼。所有患者均接受了每月3次抗VEGF药物的初始负荷剂量。此后，他们接受了至少12个月的随访治疗。在初次注射之前和之后6个月获得FA和IA图像。结果MA的中位数从早期FA中的6个（四分位数范围[IQR] 3-7）MAs显着降低，晚期FA中的3个（IQR 3-5）泄漏MAs显着降低，基线时的IA中有两个（IQR 1-4）MA，早期FA中的两个（IQR 1-3）MAs，晚期FA中的一个（IQR 0-2）泄漏MA，另一个（IQR） 0-2）晚期IA中的MA在6个月时（所有P均<0.0001）。复发性DME组（13眼）中，基线和6个月时IA晚期MA的中位数显着高于非复发性DME组（5眼）（3 [IQR 2-4] vs一[IQR 1-2]，一[IQR 0.5-2]与零[P = 0.0185和P = 0.009]）。结论玻璃体腔注射抗VEGF药物可减少DME患者的MA数量。晚期IA检测到的MA数量可能是DME复发的有用预测指标。复发性DME组（13眼）中，基线和6个月时IA晚期MA的中位数显着高于非复发性DME组（5眼）（3 [IQR 2-4] vs一[IQR 1-2]，一[IQR 0.5-2]与零[P = 0.0185和P = 0.009]）。结论玻璃体腔注射抗VEGF药物可减少DME患者的MA数量。晚期IA检测到的MA数量可能是DME复发的有用预测指标。复发性DME组（13眼）中，基线和6个月时IA晚期MA的中位数显着高于非复发性DME组（5眼）（3 [IQR 2-4] vs一[IQR 1-2]，一[IQR 0.5-2]与零[P = 0.0185和P = 0.009]）。结论玻璃体腔注射抗VEGF药物可减少DME患者的MA数量。晚期IA检测到的MA数量可能是DME复发的有用预测指标。